The type I interferon system in the development of lupus

Seminars in Immunology

Volumn 23, Issue 2, 2011, Pages 113-121

  Rönnblom, Lars ^a   Alm, Gunnar V ^b   Eloranta, Maija Leena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Environment; Gene; Immune complex; Interferon; Lupus; Plasmacytoid dendritic cell

Indexed keywords

ALPHA INTERFERON; INTERFERON;

AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; ENVIRONMENTAL FACTOR; GENE OVEREXPRESSION; GENETIC RISK; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LUPUS VULGARIS; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

AUTOIMMUNE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS;

EID: 79953161285     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2011.01.009     Document Type: Review

References (123)

1. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979, 301:5-8.
2. Ytterberg S.R., Schnitzer T.J. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982, 25:401-406.
3. Rönnblom L.E., Alm G.V., Öberg K.E. Autoimmunity after α-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991, 115:178-183.
4. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723.
5. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615.
6. Crow M.K., Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003, 5:279-287.
7. Baechler E.C., Batliwalla F.M., Reed A.M., Peterson E.J., Gaffney P.M., Moser K.L., et al. Gene expression profiling in human autoimmunity. Immunol Rev 2006, 210:120-137.
8. Krause C.D., Pestka S. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol Ther 2005, 106:299-346.
9. Gerlach N., Gibbert K., Alter C., Nair S., Zelinskyy G., James C.M., et al. Anti-retroviral effects of type I IFN subtypes in vivo. Eur J Immunol 2009, 39:136-146.
10. Li L., Sherry B. IFN-alpha expression and antiviral effects are subtype and cell type specific in the cardiac response to viral infection. Virology 2010, 396:59-68.
11. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2009, 11:373-384.
12. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
13. Fitzgerald-Bocarsly P., Dai J., Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev 2008, 19:3-19.
14. Balkhi M.Y., Fitzgerald K.A., Pitha P.M. Functional regulation of MyD88-activated interferon regulatory factor 5 by K63-linked polyubiquitination. Mol Cell Biol 2008, 28:7296-7308.
15. Baum A., Garcia-Sastre A. Induction of type I interferon by RNA viruses: cellular receptors and their substrates. Amino Acids 2010, 38:1283-1299.
16. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
17. Cristina Gauzzi M., Del Corno M., Gessani S. Dissecting TLR3 signalling in dendritic cells. Immunobiology 2010, 215:713-723.
18. Swiecki M., Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010, 234:142-162.
19. Kawai T., Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009, 21:317-337.
20. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005, 23:275-306.
21. Cao W., Manicassamy S., Tang H., Kasturi S.P., Pirani A., Murthy N., et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 2008, 9:1157-1164.
22. Gotoh K., Tanaka Y., Nishikimi A., Nakamura R., Yamada H., Maeda N., et al. Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. J Exp Med 2010, 207:721-730.
23. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005, 5:375-386.
24. Schindler C., Plumlee C. Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol 2008, 19:311-318.
25. Cho S.S., Bacon C.M., Sudarshan C., Rees R.C., Finbloom D., Pine R., et al. Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol 1996, 157:4781-4789.
26. Farrar J.D., Smith J.D., Murphy T.L., Leung S., Stark G.R., Murphy K.M. Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2. Nat Immunol 2000, 1:65-69.
27. Joshi S., Kaur S., Kroczynska B., Platanias L.C. Mechanisms of mRNA translation of interferon stimulated genes. Cytokine 2010, 52:123-127.
28. Samuel C.E. Antiviral actions of interferons. Clin Microbiol Rev 2001, 14:778-809.
29. Müller U., Steinhoff U., Reis L., Hemmi S., Pavlovic J., Zinkernagel R.M., et al. Functional role of type I and type II interferons in antiviral defence. Science 1994, 264:1918-1921.
30. Rönnblom L., Alm G.V., Eloranta M.L. Type I interferon and lupus. Curr Opin Rheumatol 2009, 21:471-477.
31. Seo Y.J., Hahm B. Type I interferon modulates the battle of host immune system against viruses. Adv Appl Microbiol 2010, 73:83-101.
32. Gao Y., Majchrzak-Kita B., Fish E.N., Gommerman J.L. Dynamic accumulation of plasmacytoid dendritic cells in lymph nodes is regulated by interferon-beta. Blood 2009, 114:2623-2631.
33. Badr G., Borhis G., Treton D., Richard Y. IFN{alpha} enhances human B-cell chemotaxis by modulating ligand-induced chemokine receptor signaling and internalization. Int Immunol 2005, 17:459-467.
34. Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234.
35. Ramos H.J., Davis A.M., Cole A.G., Schatzle J.D., Forman J., Farrar J.D. Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates. Blood 2009, 113:5516-5525.
36. Gallagher K.M., Lauder S., Rees I.W., Gallimore A.M., Godkin A.J. Type I interferon (IFN alpha) acts directly on human memory CD4+ T cells altering their response to antigen. J Immunol 2009, 183:2915-2920.
37. Stahl-Hallengren C., Jönsen A., Nived O., Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000, 27:685-691.
38. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939.
39. Crispin J.C., Liossis S.N., Kis-Toth K., Lieberman L.A., Kyttaris V.C., Juang Y.T., et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010, 16:47-57.
40. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
41. Rubtsov A.V., Rubtsova K., Kappler J.W., Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev 2010, 9:494-498.
42. Moser K.L., Kelly J.A., Lessard C.J., Harley J.B. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009, 10:373-379.
43. Flesher D.L., Sun X., Behrens T.W., Graham R.R., Criswell L.A. Recent advances in the genetics of systemic lupus erythematosus. Expert Rev Clin Immunol 2010, 6:461-479.
44. Sarzi-Puttini P., Atzeni F., Iaccarino L., Doria A. Environment and systemic lupus erythematosus: an overview. Autoimmunity 2005, 38:465-472.
45. Sebastiani G.D., Galeazzi M. Infection-genetics relationship in systemic lupus erythematosus. Lupus 2009, 18:1169-1175.
46. Munz C., Lunemann J.D., Getts M.T., Miller S.D. Antiviral immune responses: triggers of or triggered by autoimmunity?. Nat Rev Immunol 2009, 9:246-258.
47. Perl A., Fernandez D., Telarico T., Phillips P.E. Endogenous retroviral pathogenesis in lupus. Curr Opin Rheumatol 2010, 22:483-492.
48. James J.A., Kaufman K.M., Farris A.D., Taylor-Albert E., Lehman T.J., Harley J.B. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997, 100:3019-3026.
49. McClain M.T., Heinlen L.D., Dennis G.J., Roebuck J., Harley J.B., James J.A. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005, 11:85-89.
50. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
51. Casciola-Rosen L.A., Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330.
52. Rubin R.L. Drug-induced lupus. Toxicology 2005, 209:135-147.
53. Katz U., Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010, July 23 [Epub ahead of print].
54. Lee B.H., Yegnasubramanian S., Lin X., Nelson W.G. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 2005, 280:40749-40756.
55. Roberts J.L., Hayashi J.A. Exacerbation of SLE associated with alfalfa ingestion. N Engl J Med 1983, 308:1361.
56. Arnson Y., Shoenfeld Y., Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010, 34:J258-J265.
57. Costenbader K.H., Kim D.J., Peerzada J., Lockman S., Nobles-Knight D., Petri M., et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004, 50:849-857.
58. Bengtsson A.A., Rylander L., Hagmar L., Nived O., Sturfelt G. Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden. Rheumatology (Oxford) 2002, 41:563-571.
59. Jonsen A., Bengtsson A.A., Nived O., Truedsson L., Sturfelt G. Gene-environment interactions in the aetiology of systemic lupus erythematosus. Autoimmunity 2007, 40:613-617.
60. Bengtsson A., Sturfelt G., Truedsson L., Blomberg J., Alm G., Vallin H., et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not antiretroviral antibodies. Lupus 2000, 9:664-671.
61. Preble O.T., Rothko K., Klippel J.H., Friedman R.M., Johnston M.I. Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med 1983, 157:2140-2146.
62. von Wussow P., Jakschies D., Hochkeppel H., Horisberger M., Hartung K., Deicher H. MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1989, 32:914-918.
63. Han G.M., Chen S.L., Shen N., Ye S., Bao C.D., Gu Y.Y. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003, 4:177-186.
64. Bauer J.W., Baechler E.C., Petri M., Batliwalla F.M., Crawford D., Ortmann W.A., et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006, 3:e491.
65. Cederblad B., Blomberg S., Vallin H., Perers A., Alm G.V., Rönnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-α-producing cells. J Autoimmun 1998, 11:465-470.
66. Blomberg S., Eloranta M.-L., Magnusson M., Alm G.V., Rönnblom L. Expression of the markers BDCA-2 and -4 and production of interferon-α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum 2003, 48:2524-2532.
67. Robak E., Sysa-Jedrzejowska A., Robak T., Smolewski P. Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms. Clin Rheumatol 2006, 25:225-233.
68. Jin O., Kavikondala S., Mok M.Y., Sun L., Gu J., Fu R., et al. Abnormalities in circulating plasmacytoid dendritic cells in patients with systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R137.
69. Crispin J.C., Tsokos G.C. Interleukin-17-producing T cells in lupus. Curr Opin Rheumatol 2010, 22:499-503.
70. Eloranta M.L., Lövgren T., Finke D., Mathsson L., Rönnelid J., Kastner B., et al. Regulation of the interferon-a production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum 2009, 60:2418-2427.
71. Blomberg S., Eloranta M.-L., Cederblad B., Nordlind K., Alm G.V., Rönnblom L. Presence of cutaneous interferon-α producing cells in patients with systemic lupus erythematosus. Lupus 2001, 10:484-490.
72. Farkas L., Beiske K., Lund-Johansen F., Brandtzaeg P., Jahnsen F.L. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001, 159:237-243.
73. Rönnblom L., Alm G.V. The natural interferon-α producing cells in systemic lupus erythematosus. Hum Immunol 2002, 63:1181-1193.
74. Tucci M., Quatraro C., Lombardi L., Pellegrino C., Dammacco F., Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 2008, 58:251-262.
75. Denny M.F., Yalavarthi S., Zhao W., Thacker S.G., Anderson M., Sandy A.R., et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 2010, 184:3284-3297.
76. Richez C., Yasuda K., Watkins A.A., Akira S., Lafyatis R., van Seventer J.M., et al. TLR4 ligands induce IFN-alpha production by mouse conventional dendritic cells and human monocytes after IFN-beta priming. J Immunol 2009, 182:820-828.
77. Vallin H., Blomberg S., Alm G.V., Cederblad B., Rönnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999, 115:196-202.
78. Vallin H., Perers A., Alm G.V., Rönnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J Immunol 1999, 163:6306-6313.
79. Båve U., Magnusson M., Eloranta M.-L., Perers A., Alm G.V., Rönnblom L. FcγRIIa is expressed on natural IFN-α producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J Immunol 2003, 171:3296-3302.
80. Rönnblom L., Eloranta M.L., Alm G.V. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006, 54:408-420.
81. Lövgren T., Eloranta M.L., Båve U., Alm G.V., Rönnblom L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004, 50:1861-1872.
82. Munoz L.E., van Bavel C., Franz S., Berden J., Herrmann M., van der Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008, 17:371-375.
83. Pisetsky D.S., Rönnblom L. Systemic lupus erythematosus: a matter of life and death. Arthritis Rheum 2009, 60:1567-1570.
84. Tian J., Avalos A.M., Mao S.Y., Chen B., Senthil K., Wu H., et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8:487-496.
85. Lood C., Gullstrand B., Truedsson L., Olin A.I., Alm G.V., Rönnblom L., et al. C1q inhibits immune complex-induced interferon-a production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum 2009, 60:3081-3090.
86. Santer D.M., Hall B.E., George T.C., Tangsombatvisit S., Liu C.L., Arkwright P.D., et al. C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes. J Immunol 2010, 185:4738-4749.
87. Walport M.J., Davies K.A., Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998, 199:265-285.
88. Vollmer J., Tluk S., Schmitz C., Hamm S., Jurk M., Forsbach A., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005, 202:1575-1585.
89. Lövgren T., Eloranta M.L., Kastner B., Wahren-Herlenius M., Alm G.V., Rönnblom L. Induction of interferon-α by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006, 54:1917-1927.
90. Hua J., Kirou K., Lee C., Crow M.K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006, 54:1906-1916.
91. Rönnblom L., Alm G.V. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001, 22:427-431.
92. Niewold T.B., Hua J., Lehman T.J., Harley J.B., Crow M.K. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007, 8:492-502.
93. Izaguirre A., Barnes B.J., Amrute S., Yeow W.S., Megjugorac N., Dai J., et al. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukoc Biol 2003, 74:1125-1138.
94. Sigurdsson S., Nordmark G., Göring H.H., Lindroos K., Wiman A.C., Sturfelt G., et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Gen 2005, 76:528-537.
95. Sigurdsson S., Göring H.H., Kristjansdottir G., Milani L., Nordmark G., Sandling J., et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 reveals a novel 5bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008, 17:872-881.
96. Niewold T.B., Kelly J.A., Flesch M.H., Espinoza L.R., Harley J.B., Crow M.K. Association of the IRF5 risk haplotype with high serum interferon-α activity in systemic lupus erythematosus patients. Arthritis Rheum 2008, 58:2481-2487.
97. Jacob C.O., Zhu J., Armstrong D.L., Yan M., Han J., Zhou X.J., et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 2009, 106:6256-6261.
98. Shen N., Fu Q., Deng Y., Qian X., Zhao J., Kaufman K.M., et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci USA 2010, 107:15838-15843.
99. Musone S.L., Taylor K.E., Lu T.T., Nititham J., Ferreira R.C., Ortmann W., et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008, 40:1062-1064.
100. Graham R.R., Cotsapas C., Davies L., Hackett R., Lessard C.J., Leon J.M., et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 2008, 40:1059-1061.
101. Sandling JK, Garnier S, Sigurdsson S, Wang C, Nordmark G, Gunnarsson I, et al. A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE. Eur J Hum Genet; 2010 Dec 22. [Epub ahead of print].
102. Tyler D.R., Persky M.E., Matthews L.A., Chan S., Farrar J.D. Pre-assembly of STAT4 with the human IFN-α/β receptor-2 subunit is mediated by the STAT4 N-domain. Mol Immunol 2007, 44:1864-1872.
103. Remmers E.F., Plenge R.M., Lee A.T., Graham R.R., Hom G., Behrens T.W., et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007, 357:977-986.
104. Kariuki S.N., Kirou K.A., MacDermott E.J., Barillas-Arias L., Crow M.K., Niewold T.B. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-α in lupus patients in vivo. J Immunol 2009, 182:34-38.
105. Taylor K.E., Remmers E.F., Lee A.T., Ortmann W.A., Plenge R.M., Tian C., et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 2008, 4:e1000084.
106. Sigurdsson S., Nordmark G., Garnier S., Grundberg E., Kwan T., Nilsson O., et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 2008, 17:2868-2876.
107. Cunninghame Graham D.S., Akil M., Vyse T.J. Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families. Rheumatology (Oxford) 2007, 46:927-930.
108. Fawaz-Estrup F. Human parvovirus infection: rheumatic manifestations, angioedema, C 1 esterase inhibitor deficiency, ANA positivity, and possible onset of systemic lupus erythematosus. J Rheumatol 1996, 23:1180-1185.
109. Nesher G., Osborn T.G., Moore T.L. Parvovirus infection mimicking systemic lupus erythematosus. Semin Arthritis Rheum 1995, 24:297-303.
110. Båve U., Nordmark G., Lövgren T., Rönnelid J., Cajander S., Eloranta M.L., et al. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005, 52:1185-1195.
111. Eloranta M.L., Franck-Larsson K., Lövgren T., Kalamajski S., Rönnblom A., Rubin K., et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010, 69:1396-1402.
112. Biesecker G., Lavin L., Ziskind M., Koffler D. Cutaneous localization of the membrane attack complex in discoid and systemic lupus erythematosus. N Engl J Med 1982, 306:264-270.
113. Reefman E., Kuiper H., Limburg P.C., Kallenberg C.G., Bijl M. Type I interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythaematosus patients. Ann Rheum Dis 2008, 67:11-18.
114. Vermi W., Lonardi S., Morassi M., Rossini C., Tardanico R., Venturini M., et al. Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology 2009, 214:877-886.
115. Obermoser G., Schwingshackl P., Weber F., Stanarevic G., Zelger B., Romani N., et al. Recruitment of plasmacytoid dendritic cells in ultraviolet irradiation-induced lupus erythematosus tumidus. Br J Dermatol 2009, 160:197-200.
116. Båve U., Alm G.V., Rönnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer. J Immunol 2000, 165:3519-3526.
117. Akira S., Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003, 85:85-95.
118. Burnett T.J., English J.C., Ferris L.K. Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses. J Drugs Dermatol 2010, 9:1022-1024.
119. Båve U., Vallin H., Alm G.V., Rönnblom L. Activation of natural interferon-α producing cells by apoptotic U 937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 2001, 17:71-80.
120. Buyon J.P., Petri M.A., Kim M.Y., Kalunian K.C., Grossman J., Hahn B.H., et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005, 142:953-962.
121. Cohen-Solal J.F., Jeganathan V., Hill L., Kawabata D., Rodriguez-Pinto D., Grimaldi C., et al. Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus 2008, 17:528-532.
122. Li X., Xu Y., Ma L., Sun L., Fu G., Hou Y. 17beta-estradiol enhances the response of plasmacytoid dendritic cell to CpG. PLoS One 2009, 4:e8412.
123. Strandberg L., Ambrosi A., Espinosa A., Ottosson L., Eloranta M.L., Zhou W., et al. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol 2008, 28:220-231.